Understanding the VA’s Decision to Approve sTMS for Chronic Migraine
Providers often ask, “If it works, why isn’t it covered?” Let’s unpack what the VA already validated.
When healthcare providers first learn about single-pulse transcranial magnetic stimulation (sTMS) for migraine, one question tends to come up quickly:
“If the evidence is strong, why isn’t it universally covered?”
It’s a fair question. In a healthcare system where coverage decisions often shape clinical adoption, many clinicians look to payers as a proxy for clinical validation.
But in the case of neuromodulation, one of the country’s largest integrated healthcare systems reached its own conclusion years ago.
The U.S. Department of Veterans Affairs recognized that migraine represents a significant burden among veterans and began evaluating neuromodulation technologies through the lens of both clinical need and emerging evidence. Long before many commercial payers took notice, the VA was already investing in research, clinical evaluation, and access pathways for brain stimulation therapies.
Understanding why can help providers better appreciate where migraine treatment is heading.
The Evidence the VA Evaluated
The VA’s approach to emerging therapies is rooted in evidence review. Through its evidence-based assessment programs and clinical determination processes, the agency evaluates treatments based on available research, safety profiles, patient need, and potential clinical benefit.
For neuromodulation, the scientific rationale was compelling.
Research has shown that transcranial magnetic stimulation can influence cortical excitability and may interrupt mechanisms associated with migraine attacks, including cortical spreading depression—a phenomenon believed to play a role in migraine pathophysiology. Studies of sTMS have demonstrated benefits in selected migraine populations, particularly for acute treatment and, increasingly, for preventive management.
The VA’s interest was also driven by a practical reality: veterans experience migraine and headache disorders at elevated rates, often alongside traumatic brain injury, chronic pain, and other neurological conditions. As a result, there was a strong incentive to explore therapies that could provide relief without adding medication burden.
Importantly, the VA did not evaluate neuromodulation solely as an alternative therapy. It examined it as a potentially valuable addition to the treatment toolbox for patients whose needs were not fully met by conventional approaches.
Clinical Patterns Seen in Chronic Migraine
In clinical practice, chronic migraine patients often follow a familiar pattern. They have tried multiple preventive medications.
They have experienced side effects, incomplete responses, or both.
Many have reached a point where each new treatment recommendation is met with understandable skepticism.
This is where neuromodulation changes the conversation.
Rather than introducing another medication, clinicians can discuss a therapy that works through a different mechanism entirely. For some patients, that distinction matters as much as the potential clinical benefit.
The VA’s continued investment in headache and brain stimulation research reflects a broader recognition that chronic migraine management often requires multiple approaches—not simply more medications.
That perspective aligns with what many headache specialists observe every day: successful migraine care is rarely about finding one perfect therapy. More often, it involves combining tools that address different aspects of the condition.
What This Means for Non-VA Patients
The fact that the VA embraced evaluation and implementation of neuromodulation does not mean every patient will benefit from sTMS.
It is not a cure.
It does not eliminate the need for individualized treatment planning.
And it may not be appropriate for every migraine patient.
However, the VA’s experience offers an important signal to clinicians and patients alike.
It demonstrates that a major healthcare system reviewed the available evidence, recognized a meaningful unmet need, and concluded that neuromodulation warranted a place in the conversation.
For non-VA patients, the practical challenge is often access rather than scientific plausibility. Commercial coverage remains inconsistent, creating a disconnect between clinical interest and reimbursement policy.
Yet history suggests that coverage often follows evidence—not the other way around.
As more data emerge and awareness grows, providers may increasingly view neuromodulation not as a last-resort intervention, but as a legitimate component of comprehensive migraine management.
The bigger lesson may be this:
When a healthcare system responsible for millions of patients sees enough value to investigate, implement, and continue studying a therapy, it’s worth asking not why it was considered—but why more clinicians aren’t discussing it sooner.
References
- U.S. Department of Veterans Affairs. Center for Pain and Headache Research. U.S. Department of Veterans Affairs website. Accessed June 2026. Available at: https://www.va.gov/san-diego-health-care/programs/center-for-pain-and-headache-resea rch/
- U.S. Department of Veterans Affairs. Clinical Determinations and Indications (CDI). Community Care Program. U.S. Department of Veterans Affairs website. Accessed June 2026. Available at: https://www.va.gov/COMMUNITYCARE/providers/info-CDI.asp
- U.S. Department of Veterans Affairs Office of Research and Development. Magnetic brain stimulation reduces headaches in veterans. U.S. Department of Veterans Affairs website. Published October 23, 2019. Accessed June 2026. Available at: https://www.research.va.gov/news_briefs/news_brief.cfm?RecordID=258297
- Puledda F, Goadsby PJ. An update on non-invasive neuromodulation for migraine and cluster headache. Cephalalgia. 2017;37(7):685-691. doi:10.1177/0333102417702112 5. Moisset X, Pereira B, Ciampi de Andrade D, et al. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. The Journal of Headache and Pain. 2020;21(1):142. doi:10.1186/s10194-020-01204-4
- American Headache Society. Neuromodulation for Headache Disorders. American
